Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Azusa Hiura"'
1
Akademický článek
Continued Chemotherapy After Concurrent Chemoradiotherapy Improves Treatment Outcomes for Unresectable Cutaneous Squamous Cell Carcinoma: An Analysis of 13 Cases
Autor: Azusa Hiura, Koji Yoshino, Takuya Maeda, Kojiro Nagai, Satoe Oaku, Chisato Yamashita, Megumi Kato, Jiro Uehara, Yasuhiro Fujisawa
Publikováno v: Frontiers in Medicine, Vol 6 (2019)
Background: There is no standard systemic therapy for unresectable cutaneous squamous cell carcinoma (ucSCC), although various chemotherapy regimens have been reported. In our department, concurrent chemoradiotherapy (CCRT) for ucSCC resulted in a 1-
Externí odkaz: https://doaj.org/article/d9764d645e0a4e508473d991ac1e16cb
Zobrazit plný text záznamu
2
Neutrophil-to-lymphocyte ratio is associated with survival and sentinel lymph node positivity in invasive cutaneous squamous cell carcinoma: A retrospective study
Autor: Takuya Maeda, Azusa Hiura, Tomoe Nakagawa, Rino Toyoshima, Jiro Uehara, Koji Yoshino
Publikováno v: Journal of the American Academy of Dermatology. 86:615-620
Background The neutrophil-to-lymphocyte ratio (NLR) is a known prognostic biomarker for survival and is predictive of sentinel lymph node (SLN) positivity in some cancers. However, its usefulness as a prognostic biomarker for cutaneous squamous cell
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52f2c2f19afcb9ef7d3f44bf0e92d7d7
https://doi.org/10.1016/j.jaad.2021.10.033
Zobrazit plný text záznamu
5
Early tumour response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma
Autor: Azusa Hiura, R. Toyoshima, T. Nakagawa, Takuya Maeda, Jiro Uehara, Koji Yoshino
Publikováno v: The British journal of dermatologyReferences. 186(3)
Nivolumab and ipilimumab combination therapy is one of the most promising treatments for patients with melanoma. However, this combination therapy is highly toxic and causes serious adverse events (SAEs) in more than half of the patients.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39d422e48393b76891b4d1e37448b378
https://pubmed.ncbi.nlm.nih.gov/34747503
Zobrazit plný text záznamu
7
Dynamics of neutrophil and C‐reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib
Autor: Chisato Yamashita, Yasuhiro Fujisawa, Megumi Kato, Jiro Uehara, Koji Yoshino, Takuya Maeda, Kojiro Nagai, Azusa Hiura, Satoe Oaku
Publikováno v: The Journal of Dermatology. 46:716-719
Pyrexia is the most common adverse event in patients with melanoma or other solid organ malignancies that are treated with the combination of dabrafenib and trametinib (combi-DT). Given the expanded indication for combi-DT, management of pyrexia is a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1813736931ad54f196d337b66fdd137a
https://doi.org/10.1111/1346-8138.14949
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje